Coherus targets $15M quarterly LOQTORZI sales in 2026 while advancing midyear tagmokitug and casdozokitug readouts
Coherus Oncology, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.57
-8.2% in 3d after detection
Post-detection moves
1h
—
1d
-0.3%
3d
-8.2%
7d
-8.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS